

Company Announcement
ASX: HPC

DATE: 23/8/2023

Shareholder Engagement for Entitlement Offer and Registry Enhancement

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC)** (“**Hydralyte North America**” or “**the Company**”) wishes to advise that Vested Equities has been appointed as the main point of communication for Hydralyte North America’s entitlement offer announced to the market on 3 August 2023 and will be contacting shareholders to provide a strategic review update on the Company.

Vested Equities acts as a consultant to measure the overall sentiment of the shareholders assisting the company to understand how the investor relations, communications, and distribution strategy can be optimised. Shareholders can choose to update their contact details through Vested Equities to receive further correspondence and be included on the Company mailing list.

For Vested Equities please contact Harley McKinnirey, Head of Investor Relations at Vested Equities on 07 55 555 015.

ENDS

This announcement was authorised for release by the Chair of the Board of Hydralyte North America.

For further information:

Investors/Media

Henry Jordan
Six Degrees Investor Relations
0431 271 538
henry.jordan@sdir.com.au

About Hydration Pharmaceuticals Company Limited

The Hydration Pharmaceuticals Company Limited (HPC) distributes a leading range of electrolyte-rich tablets, liquid and powders originally developed in Australia under the HydraLyte brand. HydraLyte North America does not operate in Australia or New Zealand, where the brand is owned by Care Pharmaceuticals, but has exclusive rights to the HydraLyte brand in North and South America, Europe (excluding Turkey), China (excluding Taiwan) and Hong Kong, Current operations are focused on the United States and Canada, with headquarters in San Diego, California. HPC aims to grow its footprint in new international markets, led by an experienced management team and highly skilled Board of Directors.